Free tool
FAERS Monitor: Achromycin V
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050278 or its brand name (Achromycin V, Tetracycline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
779
Serious
507
65% of reports
Hospitalization
290
Death reported
212
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use226
- drug hypersensitivity154
- hypersensitivity125
- pneumonia106
- intentional product use issue104
- pain in extremity96
- vomiting95
- mobility decreased94
- arthralgia93
- neck pain91
- hepatitis88
- nausea88
- urticaria88
- drug ineffective86
- injury85
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 11 |
| 2009 | 2 |
| 2010 | 9 |
| 2011 | 10 |
| 2012 | 15 |
| 2013 | 6 |
| 2014 | 5 |
| 2015 | 16 |
| 2016 | 34 |
| 2017 | 39 |
| 2018 | 26 |
| 2019 | 42 |
| 2020 | 74 |
| 2021 | 44 |
| 2022 | 55 |
| 2023 | 62 |
| 2024 | 162 |
| 2025 | 122 |
| 2026 | 36 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,380 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatitisSignal | 88 | 93.2 | 76.5 | 7,915 |
| neck painSignal | 91 | 44.0 | 36.3 | 3,788 |
| mobility decreasedSignal | 94 | 35.4 | 29.3 | 3,112 |
| injurySignal | 85 | 32.7 | 26.7 | 2,585 |
| intentional product use issueSignal | 104 | 32.1 | 26.8 | 3,111 |
| drug hypersensitivitySignal | 154 | 21.5 | 18.7 | 3,015 |
| hypersensitivitySignal | 125 | 18.2 | 15.5 | 2,030 |
| urticariaSignal | 88 | 14.2 | 11.7 | 1,074 |
| pneumoniaSignal | 106 | 8.8 | 7.4 | 741 |
| pain in extremitySignal | 96 | 8.8 | 7.3 | 665 |
| off label useSignal | 226 | 7.0 | 6.2 | 1,199 |
| arthralgiaSignal | 93 | 6.0 | 5.0 | 394 |
| vomitingSignal | 95 | 5.5 | 4.5 | 349 |
| nauseaSignal | 88 | 3.0 | 2.5 | 120 |
| drug ineffective | 86 | 1.8 | 1.4 | 29 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.